Biogen sued for alleged PBM kickbacks scheme to boost Tecfidera in wake of generics

As Biogen’s relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive kickbacks scheme, a multi-employer health benefit plan claimed in a new lawsuit.